

Contents

1	Introduction to Ion Channels and the Cardiac Action Potential . . .	1
1.1	The Cardiac Action Potential	1
1.2	Morphology of the Action Potential in Different Parts of the Heart	2
1.2.1	Sinoatrial Node	3
1.2.2	Atria	4
1.2.3	Atrioventricular Node	5
1.2.4	His Bundle Purkinje System	5
1.2.5	Ventricle	6
1.3	Ionic Basis of Resting and Action Potential	7
1.3.1	The Uniformly Polarised Cell	7
1.3.2	Electrical Equivalent Circuit of a Cell	9
1.3.3	Equilibrium Potential	9
1.4	Properties of Ion Channels	10
1.4.1	Ion Permeation	11
1.4.2	Gating	11
1.5	Sodium Channels	12
1.6	Calcium Channels	13
1.6.1	L-Type Calcium Channel	13
1.6.2	T-Type Calcium Channel	14
1.7	Potassium Channels	14
1.7.1	Voltage-Dependent K^+ Channels	14
1.7.2	Inward Rectifier Potassium Channels	16
1.8	Stretch-Activated Channels	17
1.9	Cardiac Muscle Contraction	17
1.9.1	Cardiac Muscle Fibre	17
1.9.2	Molecular Mechanism of Contraction	22
	References	25
2	Potassium Channels Implicated in the Short QT Syndrome	33
2.1	Rectification	33
2.2	The hERG/ I_{Kr} Potassium Channel	34
2.2.1	hERG/ I_{Kr} Potassium Channel Gating	35
2.2.2	hERG/ I_{Kr} Channel Structure	36

2.3	The KCNQ1-KCNE1/ I_{Ks} Potassium Channel	38
2.3.1	KCNQ1-KCNE1/ I_{Ks} Potassium Channel Gating	40
2.3.2	KCNQ1-KCNE1/ I_{Ks} Channel Structure	40
2.4	The KCNJ2/ I_{K1} Potassium Channel	41
2.4.1	Kir2.1/ I_{K1} Potassium Channel Gating	42
2.4.2	KCNJ2/ I_{K1} Channel Structure	43
2.5	Current Profiles During an Action Potential.	44
	References	44
3	The Short QT Syndrome	51
3.1	Introduction	51
3.2	SQT1 and KCNH2	52
3.3	SQT2 and KCNQ1	54
3.4	SQT3 and KCNJ2.	55
3.5	SQT4 and SQT5.	57
3.6	Current Treatment of SQT Patients.	58
	References	60
4	Model Development	65
4.1	Modelling Voltage-dependent Channels: Hodgkin-Huxley Versus Markov Chain Models	65
4.1.1	The Hodgkin-Huxley Formalism	66
4.1.2	Markov Chain Models.	69
4.2	Development of the SQT1 Markov Model.	71
4.2.1	The Base I_{Kr} Markov Model	71
4.2.2	The SQT1 Markov Model	72
4.3	Development of the SQT2 Markov Model.	75
4.3.1	The Base I_{Ks} Markov Model	75
4.3.2	The SQT2 Markov Model	77
4.4	Development of the SQT3 Hodgkin-Huxley Model	80
4.4.1	The Base I_{K1} Model	80
4.4.2	The SQT3 Hodgkin-Huxley Model.	80
	References	82
5	Methods, Experimental Protocols and Mathematical Preliminaries	85
5.1	Experimental Protocols	85
5.1.1	Action Potential Duration, Diastolic Interval and the Basic Cycle Length.	85
5.1.2	S1-S2 Protocol.	85
5.1.3	Action Potential Duration Restitution	87
5.1.4	Effective Refractory Period Restitution	87
5.2	Governing Equations, Geometries and Associated Simulation Protocols.	87

5.2.1	Single Cell Model and AP Simulations	87
5.2.2	Heterogeneous Transmural Ventricular Tissue Model	89
5.2.3	1D Heterogeneous Transmural Strand	91
5.2.4	2D Human Ventricle Geometry	94
5.2.5	3D Human Ventricle Geometry	95
5.3	Other Simulation Protocols	96
5.3.1	Computing the Pseudo-ECG	96
5.3.2	Initiation of Re-entry in 2D sheet	96
5.3.3	Measurement of Minimal Size of S2 that Sustains Re-entry in 2D Models	96
5.3.4	Initiation of Re-entry in 2D Heart Cross-Section	97
5.3.5	Initiation of Re-entry in the 3D Anatomical Human Ventricles	97
5.4	Numerical Methods	98
	References	98
6	Increased Vulnerability of the Human Ventricle to Re-entrant Excitation in hERG Linked SQT1.	101
6.1	Introduction	101
6.2	Simulation of Single Cell I_{Kr} Under Control and SQT1 Conditions	102
6.3	Simulation of the ECG with WT and N588K Mutant I_{Kr}	111
6.4	Simulation of the Spatial Gradient of the Membrane Potential	114
6.5	Investigating the Arrhythmogenic Substrate in SQT1—1D Simulations	115
6.6	Investigating the Arrhythmogenic Substrate in SQT1: Idealised 2D Geometry Simulations	116
6.7	Investigating the Arrhythmogenic Substrate in SQT1: 2D and 3D Simulations with Realistic Geometry	119
6.7.1	Simulations in Realistic 2D Geometry	119
6.7.2	Simulations in Realistic 3D Geometry	121
6.8	Discussion and Conclusions	121
6.8.1	Summary of Major Findings	121
6.8.2	Significance of the Study	123
6.8.3	Relevance to Previous Studies	124
	References	126
7	Mathematically Modelling the Functional Consequences of the SQT2 Mutation.	129
7.1	Introduction	129
7.2	Homozygote and Heterozygote Formulations	130
7.3	Simulation of Single Cell I_{Ks} Under Control and SQT2 Conditions	131

7.4	Simulation of the ECG with WT and SQT2 Mutant I_{Ks}	136
7.5	Investigating the Arrhythmogenic Substrate in SQT2—1D Simulations	138
7.6	Investigating the Arrhythmogenic Substrate in SQT2—2D and 3D Simulations with Realistic Geometry	139
7.6.1	Simulations in 2D Realistic Geometry	139
7.6.2	Simulations in 3D Realistic Geometry	142
7.7	Investigating Blockade of I_{Ks} as a Potential Therapeutic Target in the SQT2	142
7.8	Discussion and Conclusions	145
7.8.1	Summary of Major Findings	145
7.8.2	Significance of the Study and Relevance to Previous Studies	147
7.8.3	Arrhythmogenic Mechanisms of the KCNQ1 V307L Mutation	148
7.8.4	SQT2 Treatment	149
	References	150
8	Proarrhythmia in KCNJ2-Linked Short QT Syndrome:	
	Insights from Modelling	153
8.1	Introduction	153
8.2	Simulation of Single Cell I_{K1} Under Control and SQT3 Conditions	154
8.3	Simulation of the ECG with WT, WT-D172N and D172N Mutant I_{K1}	157
8.4	Simulation of Transmural APD Dispersion and Temporal Vulnerability	160
8.5	Investigating the Conduction Velocity in SQT3	160
8.6	Investigating the Arrhythmogenic Substrate in SQT3: 1D Simulations	161
8.7	Investigating the Arrhythmogenic Substrate in SQT3: Idealised 2D Geometry Simulations	162
8.8	Investigating the Arrhythmogenic Substrate in SQT3: 2D and 3D Simulations with Realistic Geometry	163
8.8.1	Simulations with Realistic 2D Geometry	163
8.8.2	Simulations with 3D Realistic Geometry	164
8.9	Discussion	166
8.9.1	Pro-Fibrillatory Mechanisms of the Kir2.1 D172N Mutation	168
8.9.2	Relevance to Previous I_{K1} Studies	170
	References	170

9	Relationship Between Electrical and Mechanical Systole in the Short QT Syndrome: Insights from Modelling	173
9.1	Electromechanical Cardiac Myocyte Model	173
9.2	Myofilament Model	173
9.3	Coupling the Electrophysiology Model with the Myofilament Mechanics Model	174
9.3.1	Stretch-Activated Channel	175
9.4	Tissue Mechanics Model	176
9.5	The Pole-Zero Strain Energy Function	178
9.6	Mechanical Feedback in the Electrophysiology Tissue Model	178
9.7	Numerical Methods	179
9.7.1	Meshes	179
9.7.2	Electrophysiology Problem	179
9.7.3	The Mechanics Problem	180
9.7.4	Combining the Electrophysiology and Mechanics Problems	181
9.8	Single Cell Electromechanical Simulations Without I_{sac}	181
9.8.1	SQT1	181
9.8.2	SQT2	182
9.8.3	SQT3	184
9.8.4	Simulated AP Clamp	184
9.9	Single Cell Electromechanical Simulations with I_{sac}	186
9.9.1	SQT1	189
9.9.2	SQT2	192
9.9.3	SQT3	195
9.10	Tissue Simulations	197
9.11	Discussion	200
9.11.1	Simulations without I_{sac}	200
9.11.2	Simulations with I_{sac}	202
	References	203
10	Discussion and Conclusion	207
10.1	Summary of the Functional Consequences of the SQT1, SQT2 and SQT3 Variants	207
10.1.1	SQT1	207
10.1.2	SQT2	209
10.1.3	SQT3	210
10.2	Common Mechanisms Between the SQT1-3 Variants	211
10.3	Potential Limitations of the Simulations	212
10.4	Future Developments	214
10.4.1	Drug Actions	214
10.4.2	Mechanical Function	214
10.5	Closing Words	215
	References	215

Modelling the Short QT Syndrome Gene Mutations
And Their Role in Cardiac Arrhythmogenesis

Adeniran, I.

2014, XVII, 217 p. 102 illus., 38 illus. in color.,

Hardcover

ISBN: 978-3-319-07199-2